Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 9/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21604510 | 0.84 | MAP3K12 (0.52) | MAP3K12CDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL21078324 | 0.79 | MAP3K12 (0.48) | MAP3K12CDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL10896284 | 0.78 | POLB (0.34) | — | |
| SCHEMBL25087254 | 0.76 | DRD2 (0.41) | CDK2CHEK1CCNA2CCNA1HTR2A | |
| Hydrochloric Acid SCHEMBL22122657 | 0.74 | CHEK1 (0.40) | CDK2CHEK1CCNA2CCNA1HTR2A | |
| SCHEMBL15587845 | 0.74 | MAP3K12 (0.54) | MAP3K12CDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL16220058 | 0.72 | MAP3K12 (0.75) | MAP3K12 | |
| SCHEMBL12090437 | 0.72 | IKBKB (0.41) | MAP3K12IKBKB | |
| SCHEMBL21604475 | 0.70 | HTR2A (0.46) | HTR2A | |
| SCHEMBL21605728 | 0.70 | HTR2A (0.46) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9157077-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2516425-B1 | AMINOPYRIMIDINE KINASE INHIBITORS | JASCO PHARMACEUTICALS LLC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-20140080799-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2014-03-20 | — | — | US | disclosed |
| US-8563539-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2013-10-22 | — | — | US | disclosed |
| CN-102884062-A | Aminopyrimidine kinase inhibitors | JASCO PHARMACEUTICALS LLC | 2013-01-16 | — | — | CN | disclosed |
| US-20110152235-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080799-A1 | Aminopyrimidine Kinase Inhibitors | PIM1, PIM2, PIM3 | MAP3K12 81/4885CDK2 30/4885CHEK1 236/4885 |
| US-20110152235-A1 | Aminopyrimidine Kinase Inhibitors | PIM1, PIM2, PIM3 | MAP3K12 81/4885CDK2 29/4885CHEK1 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.